Literature DB >> 9677330

Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2.

M Sullivan1, G Rena, F Begg, L Gordon, A S Olsen, M D Houslay.   

Abstract

The HSPDE4A gene spans 50 kb, consists of at least 17 exons and is orientated 5'-3', telomere to centromere. It is located at chromosome 19p13.2, being 350 kb proximal to the gene encoding TYK2 and 850 kb distal to the gene encoding the low-density lipoprotein receptor. Its structure is consistent with the production of active 'long' and 'short' isoenzymes as the result of alternative mRNA splicing at two splice junctions. Identified is the single alternatively spliced 5' exon encoding the unique N-terminal region of the long isoenzyme HSPDE4A4B (pde46). The upstream conserved regions, UCR1 and UCR2, which form characteristic domains of PDE4 long forms are each encoded by three exons. The PDE4A-subfamily-specific linker region LR1, which joins UCR1 and UCR2, is encoded by two exons, whereas LR2, which joins UCR2 to the catalytic unit, is encoded by a single exon. Identification of exons encoding an enzymically inactive product of this gene, HSPDE4A8A (2el), indicates that this is an authentic gene product. The 5' exon encoding the unique N-terminal region of the human homologue of the rodent isoform RNPDE4A1A (RD1) was located, and the splice junction used to produce this short PDE4A isoform shown to occur at a different position from that seen in both the rat PDE4B and PDE4D genes. Reverse transcriptase PCR analysis indicates that RD1 homologues are conserved across species, having a conserved membrane-targeting region and a hypervariable LR2 region. Human RD1 was expressed transiently in COS-7 cells and detected as an 83 kDa species primarily associated with the high-speed membrane fraction. Human RD1 exhibited a Km for cAMP of about 3 microM, an IC50 value for inhibition by the PDE4-selective inhibitor rolipram of about 0.3 microM and was considerably more thermostable than rat RD1. Human RD1 was generated as a mature 80 kDa species in an in vitro transcription-translation system and shown to be capable of binding to membranes. Knowledge of the gene structure and the associated sequence information should facilitate analysis of the involvement of PDE4A in hereditary disorders that may result from alterations in enzyme expression, activity, regulation and intracellular targeting and serve as a resource for determining authenticity of cloned PDE4A species.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9677330      PMCID: PMC1219634          DOI: 10.1042/bj3330693

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  47 in total

1.  Assembly of a 1-Mb restriction-mapped cosmid contig spanning the candidate region for Finnish congenital nephrosis (NPHS1) in 19q13.1.

Authors:  A S Olsen; A Georgescu; S Johnson; A V Carrano
Journal:  Genomics       Date:  1996-06-01       Impact factor: 5.736

Review 2.  Tailoring cAMP-signalling responses through isoform multiplicity.

Authors:  M D Houslay; G Milligan
Journal:  Trends Biochem Sci       Date:  1997-06       Impact factor: 13.807

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Diversity in cyclic nucleotide phosphodiesterase isoenzyme families.

Authors:  V C Manganiello; T Murata; M Taira; P Belfrage; E Degerman
Journal:  Arch Biochem Biophys       Date:  1995-09-10       Impact factor: 4.013

5.  Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected].

Authors:  Y M Horton; M Sullivan; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

6.  Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites.

Authors:  L Monaco; E Vicini; M Conti
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

7.  Multiple cyclic nucleotide phosphodiesterases.

Authors:  J A Beavo; M Conti; R J Heaslip
Journal:  Mol Pharmacol       Date:  1994-09       Impact factor: 4.436

8.  Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase.

Authors:  G P Livi; P Kmetz; M M McHale; L B Cieslinski; G M Sathe; D P Taylor; R L Davis; T J Torphy; J M Balcarek
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

9.  Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases.

Authors:  K Loughney; T J Martins; E A Harris; K Sadhu; J B Hicks; W K Sonnenburg; J A Beavo; K Ferguson
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

10.  Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.

Authors:  T J Torphy; M S Barnette; D W Hay; D C Underwood
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

View more
  12 in total

1.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

2.  Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior.

Authors:  Rolf T Hansen; Marco Conti; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

3.  Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.

Authors:  S J MacKenzie; M D Houslay
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

4.  S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway.

Authors:  Leila Gobejishvili; Diana V Avila; David F Barker; Smita Ghare; David Henderson; Guy N Brock; Irina A Kirpich; Swati Joshi-Barve; Sri Prakash L Mokshagundam; Craig J McClain; Shirish Barve
Journal:  J Pharmacol Exp Ther       Date:  2011-01-25       Impact factor: 4.030

5.  Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases.

Authors:  G S Baillie; S J MacKenzie; I McPhee; M D Houslay
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

6.  Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

Authors:  M Takahashi; R Terwilliger; C Lane; P S Mezes; M Conti; R S Duman
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

Review 7.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Authors:  Miles D Houslay; David R Adams
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

8.  Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform.

Authors:  Malcolm Shepherd; Theresa McSorley; Aileen E Olsen; Lee Ann Johnston; Neil C Thomson; George S Baillie; Miles D Houslay; Graeme B Bolger
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

9.  Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change.

Authors:  Kirsty F Mackenzie; Emma C Topping; Bozena Bugaj-Gaweda; Chengjun Deng; York-Fong Cheung; Aileen E Olsen; Cecil R Stockard; Lisa High Mitchell; George S Baillie; William E Grizzle; Michael De Vivo; Miles D Houslay; Daguang Wang; Graeme B Bolger
Journal:  Biochem J       Date:  2008-04-15       Impact factor: 3.857

10.  Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.

Authors:  Matthew D Cullen; York-Fong Cheung; Miles D Houslay; Tracy L Hartman; Karen M Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Journal:  Bioorg Med Chem Lett       Date:  2007-12-14       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.